Anthropic Reports Drug Discovery Progress

Anthropic announced on October 27 (local time) progress with six organizations working on drug discovery and its own research into treatments for rare diseases. Claude is being used for molecular design, reviewing pharmaceutical manufacturing documents, and planning clinical trials. Anthropic acquired Mithril Medicine, which is developing a treatment for a rare muscular dystrophy, and is continuing its research.

Mithril Medicine was operated by its founder, Cody Tranbarger, alone. He used Claude to coordinate contracts, experiments, and logistics with 11 external research institutions. According to a preprint technical report dated October 26, Anthropic acquired the company in July 2026. The report summarizes preclinical antibody research targeting LAMA2-related congenital muscular dystrophy.

The research team designed a bispecific antibody (an antibody that binds to two targets) to reinforce the connection between the structures that support muscle fibers and muscle cell membranes. In preliminary tests using mice with a disease model, the group given one antibody had about twice the maximum strength and grip strength of the control group. These are animal study results and do not demonstrate efficacy or safety in humans.

The six partners are pursuing different projects. Generate Biomedicines is designing a shortened segment of the gene sequence for CAR-T cell therapy; Divergence Labs is designing antibody candidates for food allergies; and BigHat Biosciences is proposing candidates to improve the binding strength and stability of antibody fragments. Enveda is using Claude to review pharmaceutical manufacturing documents and prepare regulatory documents. The Column Group is forming Pleiades, a new company that will use Claude to advance multiple drug discovery programs. Bristol Myers Squibb is using Claude to plan early-stage clinical trials and assess their likelihood of success.

Enveda's CMC Document Processor (CDP) checks manufacturing records against approved procedures and similar documents, then flags sections that may require action with comments. The technical report evaluated four sets of manufacturing records, totaling 1,061 pages, from one clinical development program. CDP detected all 11 actionable issues identified by human reviewers across multiple runs. A single run using Claude Opus 4.7 also found seven additional issues that reviewers had not identified.

Processing with CDP plus human quality review took 166 minutes, about one-ninth of the 1,553 minutes (about 25.9 hours) required for manual review without assistance. AI findings are treated as recommendations; human quality teams decide how to address issues and whether manufacturing batches can be released. CDP is designed not to alter the original manufacturing records. Most of the research presented is at the preclinical stage. Anthropic said that if drug candidates continue to produce positive results, they could be ready for human clinical trials as early as the second half of 2028.

Anthropic announced on October 27 (local time) progress with six organizations working on drug discovery and its own research into treatments for rare diseases. Claude is being used for molecular design, reviewing pharmaceutical manufacturing documents, and planning clinical trials. Anthropic acquired Mithril Medicine, which is developing a treatment for a rare muscular dystrophy, and is continuing its research.

Mithril Medicine was operated by its founder, Cody Tranbarger, alone. He used Claude to coordinate contracts, experiments, and logistics with 11 external research institutions. According to a preprint technical report dated October 26, Anthropic acquired the company in July 2026. The report summarizes preclinical antibody research targeting LAMA2-related congenital muscular dystrophy.

The research team designed a bispecific antibody (an antibody that binds to two targets) to reinforce the connection between the structures that support muscle fibers and muscle cell membranes. In preliminary tests using mice with a disease model, the group given one antibody had about twice the maximum strength and grip strength of the control group. These are animal study results and do not demonstrate efficacy or safety in humans.

The six partners are pursuing different projects. Generate Biomedicines is designing a shortened segment of the gene sequence for CAR-T cell therapy; Divergence Labs is designing antibody candidates for food allergies; and BigHat Biosciences is proposing candidates to improve the binding strength and stability of antibody fragments. Enveda is using Claude to review pharmaceutical manufacturing documents and prepare regulatory documents. The Column Group is forming Pleiades, a new company that will use Claude to advance multiple drug discovery programs. Bristol Myers Squibb is using Claude to plan early-stage clinical trials and assess their likelihood of success.

Enveda's CMC Document Processor (CDP) checks manufacturing records against approved procedures and similar documents, then flags sections that may require action with comments. The technical report evaluated four sets of manufacturing records, totaling 1,061 pages, from one clinical development program. CDP detected all 11 actionable issues identified by human reviewers across multiple runs. A single run using Claude Opus 4.7 also found seven additional issues that reviewers had not identified.

Processing with CDP plus human quality review took 166 minutes, about one-ninth of the 1,553 minutes (about 25.9 hours) required for manual review without assistance. AI findings are treated as recommendations; human quality teams decide how to address issues and whether manufacturing batches can be released. CDP is designed not to alter the original manufacturing records. Most of the research presented is at the preclinical stage. Anthropic said that if drug candidates continue to produce positive results, they could be ready for human clinical trials as early as the second half of 2028.